Enhanced clinical-scale manufacturing of TCR transduced T-cells using closed culture system modules.

ABSTRACT: BACKGROUND:Genetic engineering of T-cells to express specific T cell receptors (TCR) has emerged as a novel strategy to treat various malignancies. More widespread utilization of these types of therapies has been somewhat constrained by the lack of closed culture processes capable of expanding sufficient numbers of T-cells for clinical application. Here, we evaluate a process for robust clinical grade manufacturing of TCR gene engineered T-cells. METHODS:TCRs that target human papillomavirus E6 and E7 were independently tested. A 21 day process was divided into a transduction phase (7 days) and a rapid expansion phase (14 days). This process was evaluated using two healthy donor samples and four samples obtained from patients with epithelial cancers. RESULTS:The process resulted in ~ 2000-

SUBMITTER: Jin J 

PROVIDER: S-EPMC5784598 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature